Understanding Your Diagnosis
At a Glance
NAGS deficiency is a rare inherited urea cycle disorder that allows ammonia to build up because the first step of ammonia processing is blocked. Carglumic acid can replace the missing signal, often lowering ammonia quickly, while genetic and biochemical testing helps confirm the diagnosis.
Hearing that you or your child has a condition so rare it affects fewer than one in two million people can feel overwhelming, especially if this news comes after a frightening stay in the intensive care unit [1]. It is natural to feel a mix of shock, fear, and even a strange sense of relief to finally have a name for what is happening. While estimates of its rarity vary and NAGS deficiency is exceptionally uncommon, it is also a condition with a very specific treatment [2].
What is NAGS Deficiency?
NAGS deficiency stands for N-acetylglutamate synthase deficiency. It is a type of urea cycle disorder (UCD), a group of genetic conditions that affect how the body breaks down protein [3].
Normally, when your body processes protein, it creates a waste product called nitrogen. The body’s “urea cycle” is a series of steps in the liver that turns this nitrogen into urea, which is then safely removed from the body in urine. In NAGS deficiency, the very first “spark” needed to start this cycle is missing [4].
The Missing Spark: Why Ammonia Builds Up
To understand this condition, think of the urea cycle as an engine. For the engine to start, it needs a specific key called N-acetylglutamate (NAG) [5].
- The Enzyme: Your body uses an enzyme (a functional protein) called NAGS to create this “key” (NAG) [3].
- The Problem: In people with this condition, the NAGS enzyme is either missing or not working correctly. Because the “key” isn’t made, the urea cycle engine cannot start [4].
- The Result: Because the cycle is stalled, waste nitrogen cannot be turned into urea. Instead, it remains in the body and forms ammonia, a substance that is toxic to the brain when it reaches high levels [2][6].
This buildup of ammonia is called hyperammonemia. This is what caused the medical emergency that likely led to the diagnosis [2].
A Highly Treatable Condition
While the biology of the urea cycle is complex, the treatment for NAGS deficiency is remarkably direct. Because the body is simply missing that one specific “key” (NAG), doctors can provide a replacement [7].
A medication called carglumic acid (often known by the brand name Carbaglu) acts as a substitute for the missing NAG [2]. When this medication is taken, it “unlocks” the urea cycle engine, allowing the body to process ammonia again [4].
For many patients, this treatment is highly effective and can help normalize ammonia levels quickly, sometimes within hours or days [2][1]. Because the medication works so specifically, a positive response to the drug can provide supportive evidence while biochemical and molecular results are being evaluated to confirm the diagnosis [8].
Looking Forward
Although you are dealing with a life-changing diagnosis, the outlook for NAGS deficiency is encouraging with modern treatment. Unlike some other urea cycle disorders that require extremely strict, lifelong protein restriction, many people with NAGS deficiency are eventually able to eat a more normal amount of protein once their medication dose is stable [9][1].
Your medical team—which usually includes a metabolic specialist and a specialized dietitian—will work closely with you to monitor ammonia levels and ensure the treatment is working effectively. You are not alone in this; while the condition is rare, the path forward is well-mapped by specialists who understand how to manage it.
Common questions in this guide
What is NAGS deficiency?
Why does NAGS deficiency cause high ammonia levels?
How does carglumic acid treat NAGS deficiency?
Does responding to carglumic acid prove that I have NAGS deficiency?
Will I or my child need a very low-protein diet?
What should our emergency plan include for illness or unavailable medication?
Which specialists help manage NAGS deficiency?
Get notified when new evidence is published on Hyperammonemia due to N-acetylglutamate synthase deficiency.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (9)
- 1
The efficacy of Carbamylglutamate impacts the nutritional management of patients with N-Acetylglutamate synthase deficiency.
Singh RH, Bourdages MH, Kurtz A, et al.
Orphanet journal of rare diseases 2024; (19(1)):168 doi:10.1186/s13023-024-03167-0.
PMID: 38637895 - 2
Presentation and management of N-acetylglutamate synthase deficiency: a review of the literature.
Kenneson A, Singh RH
Orphanet journal of rare diseases 2020; (15(1)):279 doi:10.1186/s13023-020-01560-z.
PMID: 33036647 - 3
N-Acetylglutamate Synthase Deficiency Due to a Recurrent Sequence Variant in the N-acetylglutamate Synthase Enhancer Region.
Williams M, Burlina A, Rubert L, et al.
Scientific reports 2018; (8(1)):15436 doi:10.1038/s41598-018-33457-0.
PMID: 30337552 - 4
Gene delivery corrects N-acetylglutamate synthase deficiency and enables insights in the physiological impact of L-arginine activation of N-acetylglutamate synthase.
Sonaimuthu P, Senkevitch E, Haskins N, et al.
Scientific reports 2021; (11(1)):3580 doi:10.1038/s41598-021-82994-8.
PMID: 33574402 - 5
Partial N-acetyl glutamate synthase deficiency presenting as postpartum hyperammonemia: Diagnosis and subsequent pregnancy management.
Abou Haidar L, Pachnis P, Gotway GK, et al.
JIMD reports 2023; (64(6)):403-409 doi:10.1002/jmd2.12388.
PMID: 37927481 - 6
Noncoding sequence variants define a novel regulatory element in the first intron of the N-acetylglutamate synthase gene.
Häberle J, Moore MB, Haskins N, et al.
Human mutation 2021; (42(12)):1624-1636 doi:10.1002/humu.24281.
PMID: 34510628 - 7
Normal Neurological Development During Infancy Despite Massive Hyperammonemia in Early Treated NAGS Deficiency.
Reigstad H, Woldseth B, Häberle J
JIMD reports 2017; (37()):45-47 doi:10.1007/8904_2017_13.
PMID: 28275973 - 8
Understanding N-Acetyl-L-Glutamate Synthase Deficiency: Mutational Spectrum, Impact of Clinical Mutations on Enzyme Functionality, and Structural Considerations.
Sancho-Vaello E, Marco-Marín C, Gougeard N, et al.
Human mutation 2016; (37(7)):679-94 doi:10.1002/humu.22995.
PMID: 27037498 - 9
Urea cycle defects in adulthood: clinical presentation, diagnosis and treatment in genetically encoded hepatic metabolic disorders with a potential for encephalopathy.
Das AM
Metabolic brain disease 2025; (40(5)):192 doi:10.1007/s11011-025-01619-5.
PMID: 40285952
This page explains NAGS deficiency, hyperammonemia, and its treatment for educational purposes only; it does not replace medical advice. Your metabolic specialist and dietitian should guide medication, protein intake, ammonia monitoring, and emergency planning.